Literature DB >> 11220367

Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: a problem of neurointensive care.

M M Treggiari-Venzi1, P M Suter, J A Romand.   

Abstract

Cerebral vasospasm remains a devastating medical complication of aneurysmal subarachnoid hemorrhage (SAH). It is associated with high morbidity and mortality rates, even after the aneurysm has been secured surgically or radiologically. A great deal of experimental and clinical research has been conducted in an effort to find ways to prevent this complication. The literature includes extensive coverage of in vivo animal model studies of SAH and vasospasm. These experimental studies have contributed to tremendous advances in the understanding of the mechanisms leading to cerebral vasospasm. Most of the experimental settings, however, have demonstrated varying levels of ability to predict accurately what occurs in human SAH. Therefore, although animal models have been developed to test new therapies, most of the treatment effects have been shown to be less compelling when trials have been conducted in clinical settings. The interpretation of current literature is complicated further by the imprecise estimation of the incidence of cerebral vasospasm, which is due to various degrees of clinical expression, ranging from the absence of symptoms in the presence of increased blood flow velocities at transcranial Doppler or vessel diameter reduction at angiography to neurological manifestations of severe ischemic deficits. In addition, a change over time in the incidence pattern of human SAH and vasospasm, possibly related to improved surgical techniques and overall patient management, may have occurred. This topic review collects the relevant literature on clinical trials investigating prophylactic therapies for cerebral vasospasm in patients with aneurysmal SAH and emphasizes the need for large clinical trials to confirm the results derived from clinical experience. In addition, it points out some experimental therapies that may hold promise in future clinical trials to prevent the occurrence of vasospasm.

Entities:  

Mesh:

Year:  2001        PMID: 11220367     DOI: 10.1097/00006123-200102000-00001

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  42 in total

1.  Intraventricular nicardipine for aneurysmal subarachnoid hemorrhage related vasospasm: assessment of 90 days outcome.

Authors:  Na Lu; Daniel Jackson; Sothear Luke; Emir Festic; Ricardo A Hanel; William David Freeman
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

2.  Non-detection of Acute Angiography-induced Cerebral Vasospasm by Transcranial Doppler Sonography amongst Patients with Subarachnoid Haemorrhage in Kelantan.

Authors:  Rozaimah Jamal; Mohd Shafie Abdullah; Nik Azhar Nik Jit
Journal:  Malays J Med Sci       Date:  2009-10

Review 3.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

4.  Role of CT perfusion imaging in the diagnosis and treatment of vasospasm.

Authors:  Edward D Greenberg; Y Pierre Gobin; Howard Riina; Carl E Johnson; Apostolos J Tsiouris; Joseph Comunale; Pina C Sanelli
Journal:  Imaging Med       Date:  2011-06-01

5.  The safety and feasibility of continuous intravenous magnesium sulfate for prevention of cerebral vasospasm in aneurysmal subarachnoid hemorrhage.

Authors:  Abutaher M Yahia; Jawad F Kirmani; Adnan I Qureshi; Lee R Guterman; L Nelson Hopkins
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

6.  Early circulating levels of endothelial cell activation markers in aneurysmal subarachnoid haemorrhage: associations with cerebral ischaemic events and outcome.

Authors:  C J M Frijns; R Fijnheer; A Algra; J A van Mourik; J van Gijn; G J E Rinkel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

7.  Can quantitative EEG reliably predict deterioration from delayed cerebral ischemia secondary to vasospasm?

Authors:  J Michael Schmidt; Jan Claassen
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

Review 8.  Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought.

Authors:  Ryszard M Pluta; Jacob Hansen-Schwartz; Jens Dreier; Peter Vajkoczy; R Loch Macdonald; Shigeru Nishizawa; Hideotoshi Kasuya; George Wellman; Emanuela Keller; Alois Zauner; Nicholas Dorsch; Joseph Clark; Shigeki Ono; Talat Kiris; Peter Leroux; John H Zhang
Journal:  Neurol Res       Date:  2009-03       Impact factor: 2.448

Review 9.  Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH.

Authors:  R M Pluta
Journal:  Acta Neurochir Suppl       Date:  2008

10.  The effect of intraventricular administration of nicardipine on mean cerebral blood flow velocity measured by transcranial Doppler in the treatment of vasospasm following aneurysmal subarachnoid hemorrhage.

Authors:  Adam Webb; Jennifer Kolenda; Kathleen Martin; Wendy Wright; Owen Samuels
Journal:  Neurocrit Care       Date:  2010-04       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.